

evaluable for response according to RECIST criteria: PR 29.4% and SD 41.2%. With a median follow-up of 3.9 months (range 0.7–11.1), median PFS was 4.6 months (95% CI: 2.6–6.6) and median OS has not been reached yet. Hematological toxicities were: 1 p gr. 3 anemia; 2 p gr. 3 and 2 p gr. 4 leucopenia; 10 p gr. 3, 1 p gr. 4 neutropenia and 3 p febrile neutropenia. Most common grade 3/4 non hematological toxicities were: vomiting (1p gr. 4), high blood pressure, asthenia and hyperglycemia. 1 p experienced gr. 4 abdominal pain, 1 p. gr. 4 constipation, 1 p. gr. 4 nausea and 1 p gr. 4 respiratory infection. No grade 3/4 hemoptysis were reported. **Conclusions:** This interim analysis shows that B in combination with cisplatin and vinorelbine is safe and well tolerated and has a promising activity in chemo-naïve p with non squamous NSCLC. Survival data will be updated.

9146

POSTER

# Long term benefit from erlotinib treatment is independent of prognostic factors and therapeutic response

C. Schumann<sup>1</sup>, D. Heigener<sup>2</sup>, I. Dittrich<sup>3</sup>, W. Abenhardt<sup>4</sup>, B. Dederke<sup>5</sup>, T. Duell<sup>6</sup>, A. Matzdorff<sup>7</sup>, B.W. Raack<sup>8</sup>, M. Steins<sup>9</sup>, C.P. Schneider<sup>10</sup>. <sup>1</sup>Universitätsklinikum Ulm Zentrum, f. Innere Medizin Klinik f. Innere Medizin II, Ulm, Germany; <sup>2</sup>Krankenhaus Großhansdorf, Abt. Onkologie, Großhansdorf, Germany; <sup>3</sup>Lungenklinik Löstau, Abt. Pneumologie II, Löstau, Germany; <sup>4</sup>Dres. Peter Bojko Wolfgang Abenhardt Daniel Bosse u.w., Dres. Peter Bojko Wolfgang Abenhardt Daniel Bosse u.w., München, Germany; <sup>5</sup>Evangel. Lungenklinik Berlin, Abt. Pneumologie, Berlin, Germany; <sup>6</sup>Asklepios Fachkliniken, Onkologie, Gauting, Germany; <sup>7</sup>Caritasklinik St. Theresia, Abt. Innere Medizin, Saarbrücken, Germany; <sup>8</sup>Praxis Bernd Wolfgang Raack, Praxis Bernd Wolfgang Raack, Celle Niedersachsen, Germany; <sup>9</sup>Thoraxklinik-Heidelberg, Abt. Innere Medizin u. Onkologie, Heidelberg, Germany; <sup>10</sup>Zentralklinik Bad Berka, Abt. Pneumologie, Bad Berka, Germany

**Background:** Erlotinib (Tarceva®) is an orally-active targeted inhibitor of the epidermal growth factor receptor. In the TRUST study, a single arm open-label phase IV trial assessing Erlotinib treatment in over 7,000 patients with advanced non small-cell lung cancer (NSCLC), the median progression-free survival was 14.3 weeks. 20% of the TRUST study patient population had a progression free survival of more than 12 months. Based on these findings we have initiated this retrospective study, performed in Germany, in order to analyze the profile of long term survivors, thus optimizing the selection of NSCLC patients which will benefit the most from Erlotinib treatment.

**Materials and Methods:** Questionnaires were retrospectively filled in by attending physicians of patients surviving over one year from the TRUST cohort in Germany. Information of patients' demographics, disease and treatment characteristics were evaluated.

**Results:** Data from 301 patients were collected. The average age of long term survivors was 66 years (range 23–87). 75% of patients were in good or moderately restricted conditions (Eastern Cooperative Oncology Group score 0 or 1). 50% of the patients received Erlotinib as second line therapy; 52% had been treated with Erlotinib for at least 18 months, and 25% were treated for over 24 months. 43% of patients were male, 14% were smokers and 33% were past smokers. Histology type was adenocarcinoma and squamous cell in 67% and 15% of patients, respectively. 56% of patients had a stable disease over the course of treatment, while 44% had partial or full response. Although 78% of patients developed a typical skin reaction, the tolerability of Erlotinib was considered good or very good by 80% of treating physicians.

**Conclusions:** The long-term benefit of this target-oriented therapy, which was predominantly very well or well tolerated, was not limited to groups with good prognostic characteristics. By contrast to conventional chemotherapy, long-term therapeutic success with Erlotinib was not restricted to patients in which complete or partial remission was induced. In summary, these data confirm Erlotinib to be effective in the long term treatment of NSCLC.

9147

POSTER

# Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression - a multicenter phase II trial of SAKK

F. Zappa<sup>1</sup>, C. Droege<sup>2</sup>, D. Betticher<sup>3</sup>, R. von Moos<sup>4</sup>, A. Ochsenbein<sup>5</sup>, R. Stahel<sup>6</sup>, D. Rauch<sup>7</sup>, P. Schmid<sup>8</sup>, M. Mayer<sup>9</sup>, M. Pless<sup>10</sup>. <sup>1</sup>Clinica Luganese Moncucco, Medical Oncology, Lugano, Switzerland; <sup>2</sup>University Hospital, Medical Oncology, Basel, Switzerland; <sup>3</sup>General Hospital, Medical Oncology, Fribourg, Switzerland; <sup>4</sup>General Hospital, Medical Oncology, Chur, Switzerland; <sup>5</sup>University Hospital, Medical Oncology, Bern, Switzerland; <sup>6</sup>University Hospital, Medical Oncology, Zurich, Switzerland; <sup>7</sup>General Hospital, Medical Oncology, Thun, Switzerland; <sup>8</sup>General Hospital, Medical Oncology, Aarau, Switzerland; <sup>9</sup>SAKK Coordinating Center, Clinical and Translational Research, Bern, Switzerland; <sup>10</sup>General Hospital, Medical Oncology, Winterthur, Switzerland

**Background:** Standard platinum-based CT for the treatment of advanced NSCLC is toxic and yields unsatisfactory results. This phase II trial aimed at evaluating the feasibility and efficacy of a first-line combination of two targeted therapies (TT), Bevacizumab (B) and Erlotinib (E), followed by standard platinum-based CT.

**Methods:** Inoperable patients (pts) with confirmed non-squamous stage IIIB or stage IV NSCLC, WHO performance status (PS) 0–1, without immediate need of CT, without large, centrally located tumors, pre-existing tumor cavitations and brain metastases were eligible. B was given at 15 mg/kg i.v. on day 1 of each 21-day cycle and E 150 mg p.o. daily until PD or unacceptable toxicity. Upon PD, patients received standard CT: gemcitabine 1250 mg/m<sup>2</sup> i.v. on days 1 and 8 q3w and either cisplatin 80 mg/m<sup>2</sup> or carboplatin AUC 5 i.v. on day 1 for a maximum of six cycles or until PD. Primary endpoint is disease stabilization (CR + PR + SD) at 12 weeks under B+E. Secondary endpoints are OS, RR, TTP, disease stabilization at 6 and 18 weeks, safety and QoL, response to subsequent CT and gene expression analysis.

**Results:** 101 eligible pts were accrued from January 9, 2006 to April 1, 2009. Median age 61y, 52.5% females, 85% stage IV, 49% PS 1, 29% never smokers. Among the 79 pts having stopped B+E, 70% continued to CT. Among 95 patients, the most frequent worst G3 toxicities during B+E were rash (3), acne (2), pruritus (2), hypertension (2), dyspnea (2, incl. one fatal) and diarrhea (2). There were 2 fatal hemorrhages and 1 cardiac failure. The median OS is 13.4 months (95% CI: 10.5–19.4 m) at a median follow-up of 17.5 m. Up to now, tumor assessments are available for 92 patients during B+E and for 53 during CT. Corresponding best RECIST-responses to first line B+E were 17.4% PR, 55.4% SD, 26.1% PD, and 1.1% early death. Best responses to 2nd line CT were 11.3% PR, 47.2% SD, 22.6% PD, and 18.9% not assessable.

**Conclusions:** Combined TT in first-line non-squamous NSCLC is feasible with acceptable toxicity and very good median OS. As the last patient was recruited on April 1, 2009, mature results of the primary endpoint and specific secondary endpoints will be available at the 2009 ESMO/ECCO meeting.

9148

POSTER

# Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

D.A. Smith<sup>1</sup>, P. Conkling<sup>2</sup>, D. Richards<sup>3</sup>, C. Alemany<sup>4</sup>, T. Boyd<sup>5</sup>, L. Garbo<sup>6</sup>, H. Wu<sup>7</sup>, D. Wages<sup>8</sup>, A. Bexon<sup>9</sup>, J. Murphy<sup>9</sup>. <sup>1</sup>US Oncology, Vancouver, USA; <sup>2</sup>US Oncology, Norfolk, USA; <sup>3</sup>US Oncology, Tyler, USA; <sup>4</sup>US Oncology, Ocoee, USA; <sup>5</sup>US Oncology, Yakima, USA; <sup>6</sup>US Oncology, Albany, USA; <sup>7</sup>US Oncology, Indianapolis, USA; <sup>8</sup>EMD Serono, Rockland, USA; <sup>9</sup>Idera Pharmaceuticals, Cambridge, USA

**Introduction:** IMO-2055, a novel synthetic TLR9 agonist, induces Th-1 type immune responses and has shown promise in providing a potential means to control tumor growth. IMO-2055 has shown additive or synergistic antitumor activity in a number of tumor models in combination with cytotoxics, targeted therapies and monoclonal antibodies, including in lung cancer xenograft studies of IMO-2055, E, and B in triple combination. Clinical trials have shown IMO-2055 monotherapy is generally well tolerated given weekly for > 1 year. We report initial results of an open label 3+3 dose finding study of the combination of IMO-2055 with E and B.

**Methods:** IMO-2055 SC is given on days (d) 1, 8, and 15 of a 3-week (w) cycle. Dosages range from 0.08 to 0.48 mg/kg/w. B is given as 15 mg/kg IV on d1 and E as 150 mg PO daily. Pts have AJCC stage 3–4 histologically proven NSCLC not amenable to curative therapy, progression during or after 1st-line treatment, with ECOG score <2. Pts with intrathoracic